Pharmacogenomics Market Size, Share Report, Analysis, Trends, Growth, 2030

 Pharmacogenomics Industry Perspective:

According to the report, global demand for the pharmacogenomics market size was valued at approximately USD 5,712.5 million in 2018 and is expected to generate revenue of around USD 10,492.2 million by the end of 2025, growing at a CAGR of around 9.2% between 2019 and 2025.

Get a Free Sample : https://www.zionmarketresearch.com/sample/pharmacogenomics-market

The report covers forecasts and analyses for the pharmacogenomics market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the pharmacogenomics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the pharmacogenomics market on a global as well as regional level.


In order to give the users of this report a comprehensive view of the pharmacogenomics market we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein the Technology and services segment is benchmarked based on their market size, growth rate, and general attractiveness.

The report provides a company market share analysis in order to give a broader overview of the key players in the pharmacogenomics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new technology launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the pharmacogenomics market on a global and regional basis.

Pharmacogenomics is the combination of pharmacology and genomics. Pharmacogenomics studies the effect of genes on drug response. The aim of pharmacogenomics is to develop safe and effective doses and medication tailored to the genetic makeup of a person.

Pharmacogenomics Market: Growth Factors

Factors such as increasing implementation of pharmacogenomics procedures, growing geriatric population, increasing adoption of personalized therapy, rapidly rising incidence of chronic disorders, and growing rate of adverse reactions will act as major driving factors in the growth of the global pharmacogenomics market. Technological advancements in the field of pharmacogenomics and increasing awareness will act as an opportunity for the market players in the pharmacogenomics market. Nonetheless, the high cost of diagnosis, lack of skilled professionals, and low awareness in developing regions will restrict the growth of the global pharmacogenomics market.

Pharmacogenomics Market: Segmentation

The global pharmacogenomics market has been split into technology, application, end-user, and region. Based on technology, the pharmacogenomics market has been segmented into microarray, polymerase chain reaction, sequencing, electrophoresis, mass spectrometry, and others. The polymerase chain reaction segment accounted for the highest market share in 2018 due to its irreplaceable nature. The application segment has been divided into infectious diseases, oncology, neurological diseases, cardiovascular diseases, pain management, psychiatry, and others. The end user segment has been divided into research institutions, hospitals and clinics, and academic institutes. The hospitals and clinics segment accounted for the highest market share in 2018 due to the presence of the latest molecular diagnostic infrastructure in hospitals.

Directly Purchase a copy of the report with TOC : https://www.zionmarketresearch.com/toc/pharmacogenomics-market

Pharmacogenomics Market: Regional Landscape

North America will be the leading region during the forecast period. The U.S. accounted for the highest share in the North American region due to the growing execution of pharmacogenomics and quick implementation of the latest healthcare technologies. Europe is likely to be the succeeding key market. The crucial reasons are the existence of skilled healthcare professionals and the increasing acceptance of personalized medicine. Asia Pacific will develop at the highest growth rate owing to the presence of the large patient group, rise in consciousness regarding pharmacogenomics, and high incidence of chronic diseases. Latin America region will propagate at a noteworthy rate through the assessment time. Middle East & Africa will show positive advancement in the projected time frame.

Pharmacogenomics Market: Competitive Space

The report also includes detailed profiles of key players such as

  • Dynamic DNA Laboratories
  • Abbott Laboratories
  • Empire Genomics
  • LLC
  • Illumina. Inc.
  • F. Hoffmann-La Roche Ltd.
  • Myriad Genetics Inc.
  • OneOme LLC
  • Thermo Fisher Scientific. Inc.
  • OPKO Health. Inc. 
  • among others.

This report segments the Global Pharmacogenomics Market as follows:

By Technology

By Application

By End User

  • Research Institutions
  • Hospitals and Clinics
  • Academic Institutes

Global Pharmacogenomics Market: By Region

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa
Contact Us:
Zion Market Research
USA/Canada Toll Free: 1 (855) 465-4651
Newark: 1 (302) 444-0166
India: +91 7768 006 007, +91 7768 006 008
Skype no: +13479038971, +17187054574
Skype no. United Kingdom: +442032894158














Comments

Post a Comment

Popular posts from this blog

1, 4 Butanediol (BDO) Market Size, Share, Trends, Growth and Forecast 2030

Image
  Description Global 1, 4 Butanediol (BDO) Market: Overview According to the report published by Zion Market Research, the global 1, 4 Butanediol (BDO) Market size was valued at  USD 7,308.99 Million  in 2022 and is predicted to reach  USD 14,089.51 Million  by the end of 2030. The market is expected to grow with a  CAGR of 8.55%  during the forecast period. The report analyzes the global 1, 4 Butanediol (BDO) Market’s growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the 1, 4 Butanediol (BDO) Market industry. 1, 4 Butanediol is an organic compound which is also known as BDO. It is colorless liquid; it has 1 out of 4 stable isomers of butanol. It is largely used as a solvent in manufacturing some types of plastic, elastic, fibers and polyurethanes. It is also used as a solvent in industrial cleaners and glue removers such as tetrahydrofuran (THF). The molecular formula for BDO contains four
Read more

Starter Fertilizers Market Size, Share, Growth Report 2030

Image
  Description The global starter fertilizers market size was evaluated at  $8.31 billion in 2022  and is slated to hit  $12.91 billion  by the end of 2030 with a  CAGR of nearly 5.66%  between 2023 and 2030. Global Starter Fertilizers Market: Overview Starter fertilizers are used in small quantity, it is placed near the seed at the time of planting. They enhance the growth of the budding seedlings by providing them with essential nutrients. They strengthen plant roots at an early stage.  Nitrogen , phosphorous, and potassium are key nutrient components present in the starter fertilizer. Phosphorous leads to the vigorous growth of the plant roots. It is widely used to maintain the phosphorous content in various crops and is especially beneficial for the corn crops. Starter fertilizers are used in cornfield production under cool soil temperatures. Get a Free Sample :  https://www.zionmarketresearch.com/sample/starter-fertilizers-market Global Starter Fertilizers Market: Growth Factors M
Read more

Global Biomarkers Market Size Share 2018 Report: Industry Type, Applications, Growth, Analysis and Forecast till 2025

Image
Global Biomarkers Market Size Share 2018 Report: Industry Type, Applications, Growth, Analysis and Forecast till 2025 There has been a dramatic increase in the value of the worldwide biomarkers market as a result of the increasing use of biomarkers in diagnostics. Increased R&D investment in pharmaceutical and biotech businesses; the growth of CROs and the low cost of clinical trials in emerging economies are all contributing to this market's rapid growth. New biomarker research projects and the high prevalence of cancer will boost this industry in the next years. On the other hand, the low cost-benefit ratio, various technological challenges connected with the collection and storage of samples, and the inadequate regulatory and reimbursement systems will likely serve as restraints on the expansion of this market in the coming years. Until now, North America has dominated the global market for biomarkers, with a significant stake. It is expected that this market will remain
Read more